Immunological analyses from the FORTE trial that compared 20 versus 40 mg dose of glatiramer acetate in multiple sclerosis

被引：0
|
作者：
Yong, V. W.
Verhaeghe, B.
Silva, C.
Myles, M. L.
Metz, L.
机构：
[1] Hotchkiss Brain Inst, Calgary, AB, Canada
[2] Univ Alberta, Edmonton, AB, Canada
来源：
MULTIPLE SCLEROSIS | 2009年 / 15卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S239 / S239
页数：1
相关论文
共 50 条
  • [31] Spanish registry of multiple sclerosis patients on glatiramer acetate 40 mg/ml treatment: Real-world results and baseline characteristics of initial patients
    Fernandez, O.
    Montalban, X.
    Rodriguez-Antiguedad, A.
    Martinez Gines, M. L.
    Casanova, B.
    Garcia, S. Moreno
    Hernandez, J. Martin
    Sanchez-de la Rosa, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 316 - 316
  • [32] 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
    O'Connor, Paul
    Filippi, Massimo
    Arnason, Barry
    Comi, Giancarlo
    Cook, Stuart
    Goodin, Douglas
    Hartung, Hans-Peter
    Jeffery, Douglas
    Kappos, Ludwig
    Boateng, Francis
    Filippov, Vitali
    Groth, Maria
    Knappertz, Volker
    Kraus, Christian
    Sandbrink, Rupert
    Pohl, Christoph
    Bogumil, Timon
    LANCET NEUROLOGY, 2009, 8 (10): : 889 - 897
  • [33] Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial
    Calkwood, Jonathan
    Cree, Bruce
    Crayton, Heidi
    Kantor, Daniel
    Steingo, Brian
    Barbato, Luigi
    Hashmonay, Ron
    Agashivala, Neetu
    McCague, Kevin
    Tenenbaum, Nadia
    Edwards, Keith
    BMC NEUROLOGY, 2014, 14
  • [34] Patient Experience with Glatiramer Acetate 40 mg/mL Three-Times Weekly Treatment for Relapsing-Remitting Multiple Sclerosis: Results from the GLACIER Extension Study.
    Kolodny, S.
    Wynn, D.
    Rubinchick, S.
    Steinerman, J. R.
    Knappertz, V.
    Wolinsky, J.
    Grinspan, A.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (03) : 417 - 418
  • [35] Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QD
    Cutter, Gary
    Veneziano, Antonella
    Grinspan, Augusto
    Al-Banna, Mahir
    Boyko, Alexey
    Zakharova, Maria
    Maida, Eva
    Pasic, Marija Bosnjak
    Gandhi, Sanjay K.
    Everts, Robin
    Cordioli, Cinzia
    Rossi, Silvia
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 40
  • [36] The Relationship Between Brain MR Spectroscopy and Disability in Multiple Sclerosis: 20-Year Data from the US Glatiramer Acetate Extension Study
    Khan, Omar
    Seraji-Bozorgzad, Navid
    Bao, Fen
    Razmjou, Sara
    Caon, Christina
    Santiago, Carla
    Latif, Zahid
    Aronov, Rimma
    Zak, Imad
    Ashtamker, Natalia
    Kolodny, Scott
    Ford, Corey
    Sidi, Yulia
    JOURNAL OF NEUROIMAGING, 2017, 27 (01) : 97 - 106
  • [37] GLACIER: open-label, randomized safety/tolerability study of glatiramer acetate 40mg/mL three times weekly versus 20mg/mL daily in RRMS
    Wolinsky, J. S.
    Dietrich, D. W.
    Borresen, T. E.
    Gilder, B. F.
    Steinerman, J. R.
    Sidi, Y.
    Vainstein, A.
    Kolodny, S.
    Knappertz, V.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 43 - 44
  • [38] Results of a randomised, double-blind, parallel-group study assessing safety and efficacy of 40 mg vs. 20 mg of glatiramer acetate on MRI-measured disease activity in relapsing-remitting multiple sclerosis
    Rovaris, M.
    Cohen, J.
    Goodman, A.
    Comi, G.
    Filippi, M.
    JOURNAL OF NEUROLOGY, 2006, 253 : 144 - 144
  • [39] Spanish registry of multiple sclerosis patients on glatiramer acetate 40 mg/ml treatment: real-world results - interim results of second year follow-up
    Fernadez-Fernandez, O.
    Rodriguez-Antiguedad, A.
    Aboin Sierra, J.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 764 - 765
  • [40] Spanish registry of multiple sclerosis patients on glatiramer acetate 40 mg/ml treatment: real-world results and initial results of first year follow-up
    Fernandez, O.
    Rodriguez-Antiguedad, A.
    Cadima, R.
    Botella, I.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 930 - 930
12345